Otsuka's tolvaptan approved in Japan
This article was originally published in Scrip
Executive Summary
Japan's ministry of health, labour and welfare has issued a formal final approval for the use of Otsuka Pharmaceutical's vasopressin V2-receptor antagonist diuretic, Samsca (tolvaptan), in patients with congestive heart failure (CHF).